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Monoclonal antibodies (mAbs), available for a range of diseases, including tumours, leukemia, andmultiple sclerosis, are emerging
as the fastest growing area of therapeutic drug development.The greatest advantage of therapeutic mAbs is their ability to bind with
a high degree of specificity to target proteins involved in disease pathophysiology. In response, effector functions are triggered and
these ameliorate the disease cascade. As an alternative to this reliance on effector functions, drugs can be conjugated to mAbs. The
ability to target compounds to the site of pathology minimises the nonspecific side effects associated with systemic administration.
In both instances, optimising the delivery, absorption, and distribution of themAbs, whilstminimising potential side effects, remain
the key hurdles to improved clinical outcomes. Novel delivery strategies are being investigated with more vigour in recent years,
and nanoparticles are being identified as suitable vehicles. In conjunction with permitting a controlled release profile, nanoparticles
protect the drug from degradation, reducing both the dose and frequency of administration. Moreover, these particles shield the
patient from the immune complications associated with high dose mAb infusions or drug cytotoxicity. This review outlines recent
advances in nanoparticle technology and how they may be of benefit as therapeutic mAb delivery/targeting vehicles.
1. Therapeutic mAbs
Therapeutic monoclonal antibodies (mAbs) are monospe-
cific antibodies designed to target proteins involved in the
pathophysiology of disease. By binding with high specificity
to these target proteins, the development/progression of the
disease is ameliorated, leading to improved clinical outcomes.
Specificity is probably the greatest advantage of mAb therapy
as the production of antibodies to specific antigenic domains
provides a mechanism to directly target the site/s of pathol-
ogy.
Therapeutic mAbs are clinically approved to treat a range
of diseases; solid tumors, including colorectal carcinoma and
squamous cell carcinoma of head/neck; haematological can-
cer, including chronic lymphocytic leukemia; inflammatory
diseases, such as rheumatoid arthritis, multiple sclerosis, pso-
riasis, asthma, and transplant rejection; and other disorders
including virus infection and wet age-related macular degen-
eration. There are >30mAb therapies clinically approved
worldwide, with current global sales at approximately $40
billion per annum. Hundreds more therapeutic mAbs are
being developed, undergoing preclinical or clinical trials to
treat other diseases or to improve existing mAb treatment
regimens.
2. Structure
The main type of therapeutic mAb is IgG, approximately
150 kDa sized Y-shaped protein structures comprised of
two heavy chains linked by disulphide bridges to two light
chains (Figure 1(a)). IgG antibodies contain two identical
antigen binding sites (Fab), each containing complementarity
determining regions (CDRs), which are variable in sequence.
IgG antibodies also contain a conserved Fc domain which
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Figure 1:The structural elements of IgG. (a)The two identical Fv (variable fragment) domains bind to the target protein with high specificity.
The Fc (constant fragment) domain binds to the Fc receptor of immune cells, triggering effector functions, including CDC and ADCC. LC =
light chain, HC = heavy chain, CDR = complementarity determining region, CL = light chain constant region, CH = heavy chain constant
region, FR = framework, VL = light chain variable region, VH = heavy chain variable region. (b) IgG murine sequence can be replaced with
human sequence to reduce immunogenicity. Commercially available mAbs include chimeric, humanised, and human IgG. Adapted from
Maynard and Georgiou, 2000 [1].
plays a role in modulating immune cell activity, including
complement activation [2], and regulating serumhalf-life [3].
Using recombinant technology, alternative mAb struc-
tures have been developed that provide specific therapeutic
benefits.The smallest functional fragments of antibodies that
can bind to the antigen (the variable regions (Fv) of both light
and heavy chains) can be joined together with a flexible pep-
tide linker to produce a single chain variable fragment (scFv;
Figure 2) [1]. The advantage of these antibody fragments
as a therapeutic mAb is a reduction in size (approximately
27 kDa), thereby allowing greater tissue penetration, which is
especially important for the treatment of solid tumors. Other
advantages include lower cost, faster manufacturing, and the
ability to better control avidity, affinity, and pharmacokinetics
[4].
Recombinant techniques have allowed antibody frag-
ments, including scFv and single domains, to bemultimerised
to produce antibodies with different sizes, valencies, and
effector functions. Two main types of antibody have been
produced; multivalent antibodies that imitate the structure of





, tribodies, and minibodies (Figure 2). Non-
IgG like structures are called heterodox and include diabod-
ies, triabodies, and tetrabodies. Other multivalent antibodies
include scFv
2
/BITEs, streptabodies, and tandem diabodies.
Therapeutic mAbs can be tagged with toxins [6] or radio-
active material [7], allowing the targeted traffic of cytotoxic
compounds to cancer cells. mAbs have also been conjugated
to anticancer compounds, including Brentuximab (anti-
CD30), which is conjugated to monomethyl auristatin E,
a potent inhibitor of microtubule polymerisation. Tositu-
momab (anti-CD20), conjugated to iodine-131, was devel-
oped for the treatment of refractory, or relapsed, follicular
lymphoma patients [7]. This antibody strategy provides a
more directed approach to destroy cancer cells than existing
methods, including chemotherapy. The only other clinically
approved therapeutic compound that contains a cytotoxic
payload is Ibritumomab (anti-CD20; non-Hodgkin’s lym-
phoma), which is also conjugated to iodine-131. These drug-
conjugated mAbs are advantageous over other mAbs as
cytotoxic compounds typically have a more pronounced bio-
logical effect than the reliance on antibody effector functions
alone, although the side effects are alsomore pronounced. For
example, Gemtuzumab, an anti-CD33 antibody conjugated
to ozogamicin, was removed from the market in 2010 due
to increased patient mortality compared to other existing
treatments.
3. Mechanism of Action
Following the binding of a mAb to the target, effector func-
tions are triggered. There are four main types of effector
functions; neutralisation, antibody-dependent cellular cyto-
toxicity (ADCC), opsonisation, and complement activation.
Neutralisation occurs when the mAb binds to the target
































Figure 2: Non-IgG mAb structures. Recombinant technology allows the manufacture of novel mAb structures that allow altered affinity,
avidity, tissue penetration, and tissue half-life. Antibody structures include fragments, orthodox (IgG-like structures), and heterodox (non-
IgG-like structures). Some antibodies are developed to contain multiple binding sites, allowing improved avidity (i.e., tandem diabody), and
different binding sites (i.e., (ScFv)
2
/BITE which can bind to two targets). ScFv = single chain variable fragment. BITE = bi-specific T-cell
engager.
protein in a surface location that prevents other protein-
protein interactions, essentially neutralising its function. In
one study, the treatment of porcine excisional wounds with a
mAb that neutralizes Flightless I, a cytoskeletal protein and
negative regulator of wound healing, resulted in accelerated
reepithelialisation and improved themacroscopic appearance
of early scars [8].
ADCCand opsonisation induce antibody-mediated cyto-
toxicity and are valuable for the treatment of both hematolog-
ical cancer and solid tumors. Both ADCC and opsonisation
are triggered when the Fc domain of the mAb is targeted to
the Fc receptor on the surface of immune cells. The binding
of the mAbs CDR to the target protein (i.e., a cell surface
protein elevated in cancer cells) along with the Fc domain
recruitment of the immune cell allows the immune cell and
target cell to be brought into close proximity, triggering che-
mokine, cytokine release, and targeted cell death.The effector
cells that may mediate ADCC include NK cells, monocytes,
macrophages, and neutrophils [9]. Rituximab, which targets
the CD20 antigen on the surface of both malignant and
normal B lymphocytes, has improved the outcome of patients
with chronic lymphocytic leukemia and non-Hodgkin lym-
phoma and has been reported to predominantly function by
the induction of ADCC [10].
Complement dependent cytotoxicity (CDC) can also be
mediated through the Fc domain and is another method of
inducing antibody-mediated cell death. CDC is dependent on
the interaction between the mAb and soluble blood proteins
that constitute the complement system [11]. Complement
activation is initiated when the mAb, already attached to the
surface of the target cell, binds to the soluble serum protein,
C1q. The activation of enzymatic activity in C1r follows C1q
binding, triggering the complement cascade and subsequent
cell death. Multiple IgG antibodies are required to be bound
to the target cell for complement cascade initiation. ADCC,
opsonisation, and CDC all appear to contribute together to
varying degrees in the cell death observed in response tomAb
treatment, due in part to the antibody isotype [12].
4. Administration Route,
Absorption, and Distribution
Parenteral delivery, intravenous injection in particular,
retains 100% bioavailability and is therefore the most com-
mon route of administration for clinically approved thera-
peutic mAbs [3, 13]. Once in circulation, the mAbs diffuse
into the peripheral tissue allowing binding to the target
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antigen. A number of mAbs are also administered subcuta-
neously, including Adalimumab (rheumatoid arthritis) and
Efalizumab (plaque psoriasis), with absorption facilitated by
the lymphatic system. This is associated with a reduction in
bioavailability but is preferred due to an ability to increase
the dose and the convenience of administration [1, 14]. The
reduction in bioavailability is predicted to be caused by the
proteolytic degradation of the mAb in either the intersti-
tial fluid or lymphatic system [4, 15]. Other less common
routes of administration are clinically approved, including
intramuscular (used for respiratory syncytial virus infection),
which also relies on absorption by the lymphatic system, and
intraperitoneal (used for malignant ascites). Some mAbs are
applied directly to the site of pathology, with Ranibizumab
administered intravitreally to treat macular degeneration.
In animal studies, dermal wounds and blisters have been
treated topically (cream) and intradermally (injected) with an
anti-Flightless mAb [5, 8, 16]. Enteral delivery has not been
adopted as a delivery route due to rapid mAb degradation
upon exposure to the gastrointestinal tract [6, 13].
5. Current Limitations of Therapeutic mAbs
Despite the recent advances in mAb therapeutics, there are
still limitations preventing effective patient treatment. One
major limitation is the cost of treatment, which is elevated due
to the cost of drug manufacture and the high dose required
for efficacy in a number of diseases. To produce mAbs, the
eukaryotic cells which secrete themAbneed to bemaintained
in culture. Extensive purification steps are also required to
producemAb under goodmanufacturing practice conditions
[7, 17].
The high dose ofmAb required per administration results
from a combination of factors associated with pharmacody-
namics and pharmacokinetics. mAbs have been shown to
be retained in circulation rather than targeted to the site
of pathology. IgG, which is larger than the renal clearance
threshold, can have a biological half-life of up to 21 days
[7, 18]. Contributing to this long half-life in circulation is
IgGs ability to bind the neonatal Fc receptor on the surface
of a number of cell types, including immune cells and the
vascular endothelium [8, 19]. The mAb is internalized into
the endosome-lysosome network of these cells, before being
exocytosed back into the serum at a later date. The process
of convection, which is the engulfment of antibody in the
bloodstream, has also been reported to retain the mAb in
circulation [9, 15].
The high dose of mAb required for therapy is also due
to the limited ability of mAb to penetrate the target tissue,
including solid tumors and the extracellular matrix, leading
to an overall low level of tissue distribution.This is caused by
the relatively large size and hydrophilic nature of the antibody
[10, 15]. Tumors in particular, where the blood supply is
viscous and there is high interstitial fluid pressure, are difficult
to penetrate [11, 17]. This has been overcome to some extent
by the use of antibody fragments, including scFv [12, 20],
which at approximately 27 kDa, are 5-fold smaller than IgG.
The effectiveness of these fragments in cancer treatment is
limited by the absence of the Fc domain, preventing antibody-
mediated cytotoxicity, but to compensate, the fragments can
be conjugated to anti-cancer drugs [21]. Another limitation
of antibody fragments as a therapeutic option is the relatively
short half-life, with Fab and scFv reported to have biological
half-lives of less than one day [17]. These fragments are
smaller than the renal clearance threshold of 70 kDa and are
therefore quickly removed from circulation.
Another limitation of mAb therapy is the binding site
barrier effect [17]. mAbs typically bind with high affinity to
the target once administered, resulting in the mAb being
immediately “mopped up” and preventing further penetra-
tion into the site of pathology [22]. This has been reported in
the treatment of solid tumors, showing suboptimal efficacy
when treated with high affinity mAbs [23]. To some extent,
this has been alleviated by the development ofmAbs that bind
with lower affinity, but this can also reduce the total amount
of mAb binding.
Hypersensitivity reactions are a common side effect of
mAb therapy, in part due to the high dose of mAb adminis-
tered, and often lead to therapy discontinuation [24].The first
therapeutic mAb, Muromonab (OKT3), a murine derived
IgG clinically approved by the FDA in 1986 to treat transplant
rejection, showed a 94% reversal in rejections, significantly
better than the conventional steroid-treatment group, and an
improved one-year graft survival [25]. However, fever, chills,
intestinal complications, convulsions, and viral infections
were identified [26]. The development of neutralizing anti-
mouse antibody responses was also observed [27]. To avoid
these complications, next generation chimerized, human-
ised, and completely human antibodies were developed that
had reduced mouse protein sequence (Figure 1(b)). As an
example, the humanised mAb, Ustekinumab, developed for
psoriasis treatment, has been reported to have a reduced
therapy discontinuation rate due to adverse effects than
equivalent patients treated with a chimeric mAb (Infliximab)
[24]. Deimmunisation, an alternative to humanization, has
been used to decrease immunogenicity [28]. In one study, the
replacement of 17 mouse residues with comparable human
residues resulted in an antibody with the same specificity
and affinity but demonstrated reduced immunogenicity [29].
Together, structural adaptations of IgG have allowed a reduc-
tion, but not complete removal, in the immune mediated
complications associated with mAb therapies.
Side effects are also associated with the administration of
drug conjugated mAbs. These toxic drugs can cause nonspe-
cific cell death on route to the site of administration, whilst
the mAb is retained in circulation or at the site of pathology.
This can be somewhat avoided by using mAbs with shorter
half-lives, although this can reduce the efficacy of treatment.
A variety of new drugs as well as alternative methods to con-
jugate the drug to the mAb are currently being investigated
to improve the safety and efficacy of these drug conjugated
mAbs [30].
Together, there are a number of limitations preventing
optimal patient treatment with therapeutic mAbs, necessitat-
ing the development of alternative methods to deliver these
drugs to the site of pathology. Recently, nanoparticle systems
have been investigated for the therapeutic delivery of drugs.
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Table 1: mAb combined with nanoparticles for a therapeutic application.
Particle type mAb SecondaryPayload Mechanism Disease Literature studies
Mesoporous
silica
𝛼-CTLA 4, 8 — mAb effector functions Melanoma Lei et al., 2010 [31]
𝛼-Mesothelin DOX Drug cytotoxicity Mesothelioma Macura et al., 2013 [32]
𝛼-EGFR Pyrrolidine-2 Drug cytotoxicity Lung cancer Sundarraj et al., 2014 [33]
TRC105 DOX/64Cu Drug cytotoxicity Tumors Chen et al., 2013 and2014 [34, 35]
Porous Silicon
Bevacizumab — Predicted for mAb effector functions Cancer Andrew et al., 2010 [36]
𝛼-MLR2 Camptothecin Drug cytotoxicity Neuroblastoma Secret et al., 2013 [37]
mAb528
(𝛼-CCL24) Camptothecin Drug cytotoxicity Glioblastoma Secret et al., 2013 [37]
Rituximab
(𝛼-CD20) Camptothecin Drug cytotoxicity B Lymphoma Secret et al., 2013 [37]
FGK45
(𝛼-CD20) — Activate B cells
Autoimmune
disease Gu et al., 2012 [38]
Gold
Tocilizumab
(𝛼-IL-6) — mAb effector functions
Rheumatoid
arthritis Lee et al., 2014 [39]
Rituximab
(𝛼-CD20) —
Photothermal ablation and mAb
effector functions Lymphoma Bisker et al., 2012 [40]
Gold Nanorods
𝛼-ICAM-1 125I Predicted for mAb effector functions Rheumatoidarthritis Shao et al., 2011 [41]
𝛼-EGFR — Infrared light induced cytotoxicity Bladder cancer Cho et al., 2014 [42]
MFNP 𝛼-HER2 — Photothermal ablation Breast cancer Shen et al., 2014 [43]
Nanographene TRC105(𝛼-CD105) —
Predicted for photothermal ablation
and mAb effector functions Breast cancer Hong et al., 2012 [44]
SPION 𝛼-neu receptor — Predicted for mAb effector functions Breast cancer Kievit et al., 2012 [45]
MFNP=multifunctional nanoparticles. SPION= superparamagnetic iron oxide nanoparticle. ICAM1 = intercellular adhesionmolecule 1. DOX= doxorubicin.
Nanoparticles offer many advantages, including protection
of the drug from degradation during delivery to the site of
pathology, controlling the rate of drug release over time and
shielding the patient from cytotoxic drugs until they reach the
site of pathology. Nanoparticles can be divided into twomain
types: polymeric, including pegylated liposomal vehicle and
albumin vehicles, and inorganic, including porous silicon and
gold nanotubes. Polymeric nanoparticles have been reviewed
elsewhere [13, 46] and some highly relevant examples of
cutting edge polymeric systems are also available [47–53] and
so will not be discussed further. However, it is important to
note that two of these polymeric preparations, Doxil (PEGy-
lated liposomal vehicle) and Abraxane (albumin vehicle),
have already been FDA approved for cancer therapy [54, 55].
In contrast, the development of inorganic nanoparticles for
mAb delivery is still in its infancy but shows great promise as
a therapeutic. This review will focus on recent developments
in the use of inorganic nanoparticles as potential therapeutic
mAb delivery vehicles.
6. Inorganic Nanoparticles for Drug Delivery
Inorganic nanoparticles are being manufactured for a wide
variety of purposes, including many promising biomedical
applications. There are now a wide variety of nanostruc-
tures being tailored for specific drug delivery applications,
including (1) the delivery of therapeutic mAbs or (2) the use
of mAbs for the targeted delivery of therapeutic payloads
(Table 1). The most common materials include mesoporous
silica nanoparticles [56], porous silicon [57, 58], silicon
nanowires [59], carbon nanotubes [60], gold nanoparticles
[61], and calcium phosphate [62] (Figure 3). Each of these
nanoparticles provides unique properties that can be tailored
to specific drug delivery or targeting applications.This review
will discuss these advantages as well as summarizing the
current literature showing the potential benefit of combining
mAbs with inorganic nanoparticles.
6.1. Advantages of Inorganic Nanoparticle Delivery Systems for
mAb Delivery and Targeting. The use of inorganic nanopar-
ticles for applications in mAb delivery presents a wide array
of advantages, with each different material including some or
all of the following.
(1) Ease of functionality with a range of surface and con-
jugation chemistries which can be carefully selected
based upon the base material used, allowing attach-
ment of various mAb structures and cytotoxic drugs.











Figure 3: Typical inorganic nanomaterials under investigation for various biomedical applications such as the localized delivery of drugs. (a)
Porous silicon nanoparticles from Secret et al. 2013 [37], (b) mesoporous silica nanoparticles from Slowing et al. 2007 [63], (c) hollow silica
nanoparticles from Deng et al. 2011 [64], (d) single walled CNTs from Kam and Dai 2005 [65], and (e) gold nanoparticles from Tiwari et al.
2014 [66].
(2) High payload loadings, which are determined by the
porosity and pore size of the material, the payload
properties, and the surface chemistry chosen.
(3) Tunable degradation rates, which are controlled by
the chosen surface chemistry and the base mate-
rial properties, and controlled release kinetics based
on the material/payload interaction and/or capping
mechanism selected.
(4) Payload protection, controlled by the ability of the
porous material to house the payload inside an inac-
cessible porous network until release, hence improv-
ing the in vivo half-life.
(5) Localized and targeted delivery, magnetically or anti-
body-targeted nanoparticles to specific tissue/disease
sites.
(6) Enhanced penetration into tissue and certain nano-
materials can be designed so that they can effectively
transverse specific tissue barriers.
(7) Exploitation of the enhanced permeation and reten-
tion effect [67, 68], where certain sized nanoparticles
naturally accumulate in tumor tissue due to the lack
of a lymphatic system, and hence, the ability to filter
particles.
(8) The ability of nanoparticle preparations to traffic
mAbs into the cytosol or other cellular compart-
ments, significantly broadening the number of anti-
gens the mAb could be designed to target, currently a
major limiting factor in mAb therapy design [69].
These advantages will be examined further for each nanoma-
terial and how they can be modified and used to enhance the
delivery or targeting of mAbs as a therapeutic option.
6.2. Mesoporous Silica Nanoparticles. Mesoporous silica
nanoparticles (MSN) are relatively biocompatible, making
them suitable for administration to patients [70, 71], although
they are not bioresorbable.Thesematerials can be synthesized
in a controlled manner allowing for the modification of pore
shape and surface chemistry [72, 73], importantly allowing
for the attachment of different mAb structures. Ultralarge
pores have been produced [74], and this allows high capacity
loading of mAbs.
Functionalized MSN has been loaded with a mAb raised
to CTLA 4, 8, a protein elevated on the surface of tumor cells,
and administered to mice with melanoma [31]. The admin-
istration of these particles showed an increased inhibition
of tumor growth compared to the systemic administration
of mAb alone. These results demonstrated that loading mAb
into MSN did not alter the mAb effector functions, and by
facilitating sustained antibody release, the half-life of the
mAb was prolonged at the tumor site.
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MSN loaded with a mesothelin specific antibody was
administered to mice with malignant mesotheliomas [32].
In this study, the particles were loaded with the cytotoxic
drug, doxorubicin (DOX). The mesothelin specific antibody
successfully targeted the MSN to tumor sites after intraperi-
toneal injection. It was observed that the targeted MSN
were more effective than DOX alone and were able to help
reduce the side effects of DOX treatment. Sundarraj et al.
[33] have also conjugated epidermal growth factor receptor
antibody toMSN to target lung cancer cells.Their system then
released the cytotoxic drug, pyrrolidone-2, showing a 38%
enhancement in tumor inhibition. The system also showed
low systemic toxicity.
MSN have been capped with gatekeepers, including chi-
tosan-PEG copolymers, to regulate payload release, with this
controlled by environmental changes at the site of pathology
[75, 76]. Deng et al. [64] have used pH sensitive chitosan in
combination with hollow silica nanospheres to deliver pro-
tein payloads.The targeting antibody, ErbB2, was conjugated
to the outer regions of the chitosan coating, allowing tar-
geting to breast cancer cells. When administered to mice,
there was elevated payload release in tumors (at pH 4) when
compared to normal tissue (at pH 7.4). This system may be
useful for the delivery of mAbs not just to tumors but also
to other sites of pathology where pH change may indicate a
worsening pathology, including chronic wounds.
6.3. Porous Silicon. Porous silicon (pSi) is a high surface area
(800m2 g−1 [77]) biomaterial produced via the electrochem-
ical etching of crystalline silicon wafers in hydrofluoric acid
electrolyte solutions [77]. The pore size can be varied from
5 nm to 1-2 𝜇m based on the careful selection of fabrication
parameters [77]. pSi can also be manufactured in many
different morphologies such as films, membranes, micropar-
ticles, and nanoparticles [78] and is easily functionalizedwith
readily available chemistries [79–83].
Andrew et al. [36] have demonstrated the loading of
therapeutic mAb into pSi. In this study, 800∘C oxidized
pSi films were effectively loaded with a high concentration
of Bevacizumab, a mAb raised against vascular endothelial
growth factor A.The controlled release of 94% of the payload
was demonstrated over a 30-day period, with no initial burst
release observed. Importantly, the released mAb retained its
functionality as demonstrated by ELISA. Further studies are
required to demonstrate the efficacy of these mAb-loaded
particles in vivo.
Another study has demonstrated the attachment of anti-
bodies to pSi, providing a targeting mechanism to deliver the
cytotoxic agent, camptothecin [37]. Here, antibodies raised
against cell-specific surface receptors were covalently grafted
to the surface of pSi nanoparticles, allowing different cancer
cell lines to be selectively targeted, namely, neuroblastoma
(MLR2), glioblastoma (mAb528), and B lymphoma (Ritux-
imab). The antibody-functionalized pSi nanoparticles selec-
tively killed cells expressing the target receptor, therefore
providing a promising therapeutic application. In another
study, Gu et al. combined luminescent pSi nanoparticles
with the FGK45 antibody, which activates B cells. They
demonstrated that when this agonistic antibody was attached
to the pSi nanoparticles, the activation of B cells was 40%
higher compared to just free FGK45 antibody [38]. This is
the first time an effect like this has been observed and could
lead to a decrease in dosages required. The clever use of
luminescent pSi nanoparticles by the authors also allows the
nanoparticles to be readily tracked.
6.4. GoldNanoparticles. There are a number of gold nanopar-
ticle systems, including nanorods [41, 42], multifunctional
nanoparticles containing a gold nanoshell [43], and tradi-
tional spherical nanoparticles [39, 40], that have been loaded
with therapeutic mAbs. Developed to target rheumatoid
arthritis and various cancers, these mAb-loaded particles
show high specificity to the target cells [43] with low toxicity
and retain antibody functionality [40]. Gold nanoparticles
loaded with Tocilizumab (𝛼-IL-6) have been used to treat an
inducible rheumatoid arthritis mouse model, showing low-
ered IL-6 levels and a significant reduction in disease severity
score [43]. In another study, gold nanorods loaded with a
mAb that targets bladder cancer cells were administered via
a urine catheter, followed by exposure to infrared light [42].
This treatment showed rapid clearance of bladder cancer cells.
mAb-loaded gold nanorods have also been radiolabelled,
enabling optical and nuclear imaging of the target tissue [41].
One major advantage of gold nanoparticles is the ability to
use hyperthermia to destroy the target cells [40].This involves
the application of a continuous-wave near infrared laser and
is especially useful in tumor treatment. This technique has
fewer side effects than the use of cytotoxic drugs, which can
kill cells nonspecifically and are retained in the patient until
being metabolised.
6.5. Carbon-Based Nanomaterials. Carbon-based materials,
such as nanographene, have modifiable surface chemistries,
can be produced with ultra-high surface areas for drug load-
ing, and also have unique electrical and optical properties.
In one study, nanographene particles were bound to the
mAb, TRC105, which binds to CD105, a vascular marker for
tumor angiogenesis [44]. When administered to a mouse
model of cancer, there was effective nanoparticle targeting
to the tumor. One major advantage of these particles is the
capacity to use noninvasive positron emission tomography
(PET) imaging to visualize the in vivo localisation of the
nanographene. Similar to gold nanomaterials, photothermal
therapy can also be used with nanographene particles, pro-
viding a therapeutic option for tumors.
Carbon nanotubes (CNTs) can bemodified with a variety
of surface chemistries, are soluble, biocompatible and allow
protein binding [84, 85]. Importantly, a number of research
groups have demonstrated the ability of CNTs to traffic bound
protein across cell membranes [65, 86]. For example, Kam
and Dai [65] have absorbed cytochrome C, streptavidin,
protein A, and BSA to the walls of single walled CNTs that
had been acid oxidized. They showed generic uptake into 4
cell lines, HeLa, NIH-3T3, HL60, and Jurkat cells. This was
the first work to demonstrate the in vitro biological function
of proteins delivered to the cytosol via CNTs. This property
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may be exploited for the delivery of therapeutic mAbs to
intracellular locations.
6.6. Magnetic Nanoparticles. Superparamagnetic iron oxide
nanoparticles (SPIONs) are a type of magnetic nanoparticle
that can be functionalized, has near neutral zeta-potential,
is large enough to avoid renal clearance, and is stable [45].
In one study, SPIONs were conjugated to an antibody raised
against neu, a protein overexpressed in metastatic breast can-
cer. Inmice, the SPIONs showed preferential association with
mammary carcinoma cells. Superparamagnetism is impor-
tant property of metal oxide nanoparticles as it allows the
targeting of SPIONs to be visualized by MRI contrast agents
[87]. This was observed when the neu-targeted SPIONs were
administered to mice, showing enhanced MRI detection of
small metastases.The ability tomonitor, treat, and potentially
diagnosemetastatic breast cancer with the one system has the
potential of providing an enormous benefit to cancer patients.
7. Conclusion
Inorganic nanoparticles present an exciting opportunity
for both therapeutic mAb delivery and the use of mAbs
to target drugs payloads. For the delivery of therapeutic
mAb, porous nanomaterials, such as pSi and MSN, have the
capacity to hold large payloads, whilst providing a sustained
release specifically tuned for optimal clinical efficacy. These
particles provide themAb protection fromdegradation, renal
clearance, and retention in circulation by convection. The
slow release of the mAb enables a reduction in the frequency
of administration, which will reduce the cost of therapy and
minimise side effects. There is also a strong likelihood that
the binding side barrier effect will be decreased. For the use
of mAbs as a targeting tool, inorganic nanoparticles provide
protection for the payload, allow a large variety of compounds
to be loaded, enable the option of photothermal ablation,
and can be used as gatekeepers to control payload release.
mAbs can be effectively loaded into a variety of inorganic
particles, retaining their functionality, with minimal side
effects. These particles have been successfully targeted to the
site of different pathologies. Importantly, clinical efficacy has
been demonstrated in a number of mouse models of disease,
including the treatment of tumors. These nanoparticles pro-
vide a host of other beneficial features, including the ability of
some to naturally target tumors, cell penetrating properties,
the use of PET to visualize the particles noninvasively, and
their ability to target cells for death using photothermal
ablation.
The ability to now combine many of these materials
together into one device or delivery system and impart dual
functionality is leading to the development of theranostic
systems (including diagnosis, treatment, and monitoring of
the disease). One could eventually imagine mAb-loaded par-
ticles floating through the blood stream or lying in wait
until a disease state is detected, giving the body a potential
immediate response, before the disease progresses beyond
its initial phase. The continued development of these smart
systems will eventually lead to more clinically beneficial and
cost effective therapies for a wide range of diseases.
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